Autoantibody Profiling in Cardiomyopathies: Toward Immune-Guided Risk Stratification and Therapy
Journal of Clinical Medicine · 29.03.2026 · 15 (7) · 2615
DOI: 10.3390/jcm15072615 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.03.2026. Verfasst von Alberto Marmai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Division, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, DSCTV.
Abstract (Originalsprache)
Cardiomyopathies comprise a heterogeneous group of myocardial disorders characterized by structural and/or functional abnormalities in the absence of secondary causes of myocardial dysfunction. Although genetic determinants play a central role in many forms of the disease, incomplete penetrance and the frequent absence of identifiable pathogenic variants suggest that additional mechanisms contribute to disease onset and progression. Growing evidence supports the pathogenic role of autoimmune processes in several cardiomyopathy phenotypes. A spectrum of autoantibodies targeting cardiac self-antigens, including structural proteins, intercalated disc components, intracellular proteins such as calreticulin, and G protein-coupled receptors, has been identified in affected patients. Experimental and clinical data suggest that these autoantibodies may exert functional effects on cardiomyocyte signaling pathways and intercellular coupling, thereby promoting maladaptive remodeling, progressive ventricular dysfunction, and an increased risk of arrhythmias. Accordingly, autoantibody profiling may facilitate the identification of biologically distinct cardiomyopathy subsets with potential diagnostic and prognostic implications. From a therapeutic perspective, pathogenic autoantibodies can be removed from patient serum through plasmapheresis or immunoadsorption strategies, and these approaches have been associated with improvements in hemodynamic parameters and clinical outcomes in selected patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Division, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.
- PhD Program in Translation Specialistic Medicine "G.B. Morgagni", Curriculum "Cardiovascular Sciences", University of Padua, 35128 Padua, Italy.
- Translational Biomedicine Group, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.
- Transplant Immunology Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.
ORCID-Profile: Alberto Marmai, Giovanni Civieri, Laura Iop, Francesco Tona
Förderung
- Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua
- DSCTV
Zitieren
APA
Marmai, A., Civieri, G., Iop, L., Martini, M., Vadori, M., Cozzi, E., & Tona, F. (2026). Autoantibody Profiling in Cardiomyopathies: Toward Immune-Guided Risk Stratification and Therapy. Journal of Clinical Medicine, 15(7), 2615. https://doi.org/10.3390/jcm15072615
Vancouver
Marmai A, Civieri G, Iop L, Martini M, Vadori M, Cozzi E, et al. Autoantibody Profiling in Cardiomyopathies: Toward Immune-Guided Risk Stratification and Therapy. Journal of Clinical Medicine. 2026;15(7):2615. doi:10.3390/jcm15072615
BibTeX
@article{Marmai2026,
author = {Marmai, Alberto and Civieri, Giovanni and Iop, Laura and Martini, Marika and Vadori, Marta and Cozzi, Emanuele and Tona, Francesco},
title = {Autoantibody Profiling in Cardiomyopathies: Toward Immune-Guided Risk Stratification and Therapy},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {7},
pages = {2615},
doi = {10.3390/jcm15072615}
}
EUVIMED